MedPath

Bioactive Glass in the Treatment of Enamel White Spot Lesions

Phase 3
Completed
Conditions
White Spot Lesion of Tooth
Interventions
Drug: BiominF
Drug: Novamin
Drug: CPP-ACP
Registration Number
NCT04401280
Lead Sponsor
Rania Salah
Brief Summary

the aim of this study is to evaluate the effectiveness of BiominF® and Novamin® in comparison to Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in the treatment of enamel white spot lesions

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Not less than 1 white spot lesion on the labial surface of teeth in the anterior region with code 2 International Caries Detection and Assessment System II (ICDAS-II) or less
  • Absence of any active periodontal disease.
  • Written informed consent
Exclusion Criteria
  • Known hypersensitivity/allergy to study products and/or materials used
  • teeth having deep carious lesions or extensive restorations
  • Unwillingness to be randomly assigned to 1 of the 3 treatment groups
  • Advanced periodontal disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BiominF®BiominFTest group
Novamin®NovaminTest group
CPP-ACPCPP-ACPControl group
Primary Outcome Measures
NameTimeMethod
Change in White spot lesions dimension6 months: (Baseline, 1 week, 1 month, 3 months, 6 months)

Quantified using computer-assisted analysis based on digital intraoral photographs

Secondary Outcome Measures
NameTimeMethod
change in lesion fluorescence6 months: (Baseline, 1 week, 1 month, 3 months, 6 months)

evaluated using diode laser fluorescence device (Diagnodent)

Trial Locations

Locations (1)

Faculty of Dentistry

🇪🇬

Alexandria, Egypt

© Copyright 2025. All Rights Reserved by MedPath